What is startup capital?

Startup capital: the plain-English definition

Startup capital is the money a new company uses to start operating and reach specific milestones—typically from “idea” to a product that customers will buy and that can be delivered safely and legally.

Think of it as the fuel that pays for people, tools, testing, and time before the business reliably generates cash from sales. In business terms, it covers your runway (how many months you can operate before you run out of cash) and helps you reduce key risks (technical, clinical, regulatory, and commercial).

In medtech and digital health, startup capital often has a different shape than in consumer apps because you may need evidence, regulatory clearance, and reimbursement strategy before revenue is realistic.

What startup capital pays for in medtech (real categories)

Startup capital isn’t just “building the product.” For clinician- and engineer-led teams, the surprise is how much of the budget goes to validation, compliance, and selling into hospitals.

• Team and contractors: engineering, clinical advisors, quality/regulatory consultants, fractional finance, and sometimes a part-time sales lead.
• Prototype + iteration: industrial design, electronics/firmware, app development, cloud hosting, and lab supplies.
• Quality system setup: documentation, design controls, risk management, and vendor qualification (often aligned with ISO 13485 practices, depending on your device and market).
• Verification & validation (V&V): bench testing, usability testing, cybersecurity testing (for connected devices), and reliability testing.
• Regulatory pathway work: preparing a 510(k), De Novo, or PMA strategy; pre-submission planning; and compiling the technical file. Which pathway applies depends on your intended use, risk class, and predicate availability.
• Clinical evidence: IRB approval (if needed), study operations, data capture, and analysis. Even for software, evidence expectations vary by claims and risk.
• Reimbursement groundwork: mapping billing and payment (e.g., whether CPT codes exist, whether you need a new code, and who the payer is). Reimbursement can be the difference between “nice pilot” and “real purchasing.”
• Go-to-market costs: hospital procurement onboarding, security reviews, vendor contracts, and early customer success. Selling to hospitals is often slower than founders expect.
• Legal and admin: incorporation, IP strategy, contracts, insurance, and basic accounting.

A useful mental model: in medtech, capital is frequently spent to buy down risk—proving safety, performance, and economic value—so that customers, regulators, and investors can say “yes.”

Where startup capital comes from (and what it “costs” you)

Capital sources differ mainly by (1) how fast you can access the money, (2) what you give up (equity, control, repayment), and (3) what milestones the funder expects.

Common sources

• Bootstrapping: your savings or operating revenue. Cheapest in terms of ownership, but limited runway.
• Friends & family: early checks based on trust. Use clear terms to avoid relationship damage.
• Non-dilutive funding: grants, competitions, and some strategic programs. “Non-dilutive” means you don’t give up equity, but timelines and reporting can be heavy and amounts vary.
• Angels: individuals investing for equity, often helpful for early medtech credibility and introductions.
• Seed / venture capital (VC): institutional investors seeking high growth. Typically expects a big market, a scalable business model, and a credible regulatory/reimbursement plan.
• Strategic partners: device companies or health systems that may fund pilots, development, or distribution. Great leverage, but watch exclusivity and IP terms.
• Debt: loans or venture debt. Usually requires predictable revenue or strong backing; risky if you don’t have cash flow.

Dilution (jargon explained)

Dilution means your ownership percentage goes down when you issue new shares to investors. Example: if you own 100% and raise money by selling 20% of the company, you now own 80%. Dilution isn’t automatically bad—if the capital helps you reach milestones that increase the company’s value, your smaller percentage can be worth more.

How much startup capital do you need? Use a milestone-based budget

In medtech, “how much do I need?” is best answered as: how much to reach the next value-inflection milestone. A value-inflection milestone is something that materially reduces risk or unlocks the next funding/customer step (e.g., a working prototype, a completed usability study, a defined FDA pathway, a signed pilot with a health system, or a reimbursement plan tied to existing CPT codes).

Build your capital plan backwards from milestones:

1. Pick the next 1–2 milestones that make fundraising or sales easier.
2. List the workstreams: product, quality/regulatory, clinical evidence, reimbursement, and go-to-market.
3. Estimate monthly burn (your “burn rate” is how much cash you spend per month).
4. Add time buffers for hospital timelines, IRB cycles, and vendor delays (these often vary widely).
5. Raise for runway that covers the plan plus a buffer, because fundraising itself takes time.

For example, a digital health product making clinical claims may need capital for security, privacy, clinical evaluation, and integration work—while a device may need more for prototyping, testing, and regulatory documentation. The right number varies by risk class, pathway (510(k) vs De Novo vs PMA), and how much you can do with in-kind support.

Medtech-specific traps: where founders underestimate capital

• Regulatory is not a “final step”: decisions you make early (intended use, claims, risk classification) drive testing and documentation later.
• Evidence expectations: even if FDA clearance isn’t required for your first version, customers may demand clinical validation, SOC 2-style security posture, or outcomes data.
• Hospital procurement friction: security questionnaires, vendor onboarding, and contracting can take months and consume founder time (which is also “capital”).
• Reimbursement reality: without a payment path, pilots can stall. Understanding whether existing CPT codes apply (or whether you’re in a cash-pay or enterprise licensing model) changes your capital needs.
• Quality system debt: skipping documentation early can create expensive rework later, especially if you move toward 510(k), De Novo, or PMA submissions.

What to do next

1. Write your next milestone in one sentence (e.g., “bench-tested prototype + defined 510(k) strategy” or “signed pilot + IRB-approved study protocol”).
2. Build a 12-month burn plan with 5–8 line items (people, contractors, testing, regulatory, clinical, cloud/tools, legal, go-to-market) and a buffer.
3. Choose your capital mix: decide what you can bootstrap, what should be non-dilutive, and what requires equity funding.
4. Pressure-test your assumptions about FDA pathway, IRB needs, and reimbursement with a short expert call or advisor review.
5. Prepare a simple investor-ready narrative: problem, solution, evidence plan, regulatory path (510(k)/De Novo/PMA as applicable), reimbursement angle, and why your team can execute.

If you want, share your product type (device vs SaMD), intended users (clinicians vs patients), and whether you expect FDA involvement, and I’ll outline the most likely capital milestones and budget categories.